Анализ Simply Wall St: акции Oscar Health (OSCR) значительно недооценены при росте прибыли на 361,8 млн долларов

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Oscar Health (OSCR) is back in focus after reporting second quarter 2026 results that swung from a loss to net income of $361.81 million and raising full year earnings guidance. See our latest analysis for Oscar Health. Oscar Health shares have been volatile around the earnings release, with an 11.9% drop reported after the outlook update. The stock still shows a 118.84% year to date share price return and a 109.46% 1 year total shareholder return, suggesting momentum remains strong despite concerns over second half utilization, risk adjustment and churn. If Oscar Health's move has you rethinking your watchlist, this could be a good moment to scan for other healthcare technology opportunities through our curated 44 healthcare AI stocks The swing in Oscar Health's results and guidance points to real business progress, yet the sharp pullback hints at a reset in sentiment. How does that mix of fundamentals and mood show up in today's valuation? Most Popular Narrative: 94.4% Undervalued At a last close of $32.76 versus a narrative fair value of $583.34, Oscar Health screens as heavily undervalued on one widely followed valuation framework. That gap raises clear questions about the assumptions behind such an aggressive target. Suspicious of a value trap, I started digging into the operational engine to find the catch. Instead, the deeper I dug, the more the moat began to show: Capital Efficiency: The business generates a powerful 27.9% return on invested capital (ROIC), even while operating on a razor-thin 4.1% operating margin. Cash: Out of USD $15.32 billion in trailing revenue, an estimated 28.6% converts into cash flow. Balance Sheet: Total debt sits at a microscopic 0.21 times equity. In absolute terms, they are holding a USD $3.64 billion net cash position. If the market turns hostile, this cash could extend their survival time relative to more heavily levered competitors. This narrative on Oscar Health centers its fair value on cash conversion, capital efficiency and a balance sheet cushion. It raises the question of which growth and margin paths would need to align to support that level of upside. Result: Fair Value of $583.34 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Oscar Health's story could change quickly if medical cost trends, churn, or regulatory shifts weaken those cash conversion and capital efficiency assumptions.